BioMarin completes Amicus acquisition for USD 14.5 per share, valuing deal at USD 4.8 billion
PUBT · 5d ago
Share
Listen to the news
- BioMarin completed acquisition of Amicus Therapeutics in an all-cash deal priced at USD 14.5 per share.
- Total equity value of transaction was about USD 4.8 billion.
- Deal adds Fabry disease drug Galafold to BioMarin commercial portfolio.
- Transaction also brings Pompe disease therapy Pombiliti with Opfolda.
- BioMarin expects to provide updated FY 2026 guidance during first-quarter earnings call on May 4, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604270844PR_NEWS_USPR_____SF43684) on April 27, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved